Actually AGN was around $50m 2 years ago.
Two and a half years ago it spiked to nearly $100m for a brief period.
NYR was $30m 2 years ago and nearly $70m 3 years ago.
AGN has continued to range between $40m and $85m for the last couple of years. That's actually not bad given the overall trend for the biotech sector - see previous post for reasons why AGN SP has done OK (compared to NYR).
Ann: Nyrada Commences Walter Reed Traumatic Brain Injury Study, page-107
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $78.03M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1642 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 682527 | 2 |
View Market Depth
| Last trade - 07.10am 01/08/2025 (20 minute delay) ? |
| NYR (ASX) Chart |
Day chart unavailable